Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Eric Aguiar sold 3,537 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $55.13, for a total value of $194,994.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Eric Aguiar also recently made the following trade(s):
- On Monday, December 9th, Eric Aguiar sold 4,072 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $55.11, for a total value of $224,407.92.
- On Wednesday, November 20th, Eric Aguiar sold 6,729 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $52.20, for a total value of $351,253.80.
- On Friday, November 22nd, Eric Aguiar sold 1,250 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $55.24, for a total value of $69,050.00.
Shares of NYSE BHVN traded down $0.99 during midday trading on Wednesday, reaching $52.13. The company had a trading volume of 580,883 shares, compared to its average volume of 712,597. Biohaven Pharmaceutical Holding Co Ltd has a one year low of $29.17 and a one year high of $67.86. The firm’s fifty day moving average price is $51.94 and its 200-day moving average price is $46.53. The stock has a market cap of $2.74 billion, a PE ratio of -8.48 and a beta of 0.46.
Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings results on Friday, November 1st. The company reported ($2.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.47). As a group, research analysts anticipate that Biohaven Pharmaceutical Holding Co Ltd will post -7.55 earnings per share for the current fiscal year.
Several equities analysts have recently commented on BHVN shares. ValuEngine upgraded Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday, December 7th. Zacks Investment Research downgraded Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. William Blair reaffirmed a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, December 10th. Canaccord Genuity set a $80.00 price target on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Monday, August 26th. Finally, Goldman Sachs Group set a $89.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Biohaven Pharmaceutical currently has a consensus rating of “Buy” and a consensus target price of $71.42.
Hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC boosted its stake in shares of Biohaven Pharmaceutical by 511.1% during the third quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $46,000 after purchasing an additional 920 shares during the period. Tower Research Capital LLC TRC purchased a new position in shares of Biohaven Pharmaceutical in the second quarter worth $65,000. Aperio Group LLC purchased a new position in shares of Biohaven Pharmaceutical in the second quarter worth $71,000. Glen Harbor Capital Management LLC raised its holdings in Biohaven Pharmaceutical by 165.9% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock valued at $76,000 after buying an additional 1,088 shares during the last quarter. Finally, Canton Hathaway LLC bought a new stake in Biohaven Pharmaceutical during the 3rd quarter valued at $83,000. Hedge funds and other institutional investors own 92.83% of the company’s stock.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Recommended Story: Liquidity
Receive News & Ratings for Biohaven Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.
